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Abstract 
 
Objectives: 
To assess the relative efficacy of bisphosphonates (alendronate, risedronate, ibandronate and 
zoledronic acid) for the treatment of osteoporosis using network meta-analysis (NMA). 
 
Methods: 
A systematic review of the literature was conducted using PRISMA guidelines. A network 
meta-analysis was used to determine the relative efficacy of treatments on four fracture 
outcomes (vertebral, non-vertebral, hip and wrist) and percentage change in femoral neck 
bone mineral density (BMD). Treatment effects were modelled using an exchangeable 
treatment effects model. Heterogeneity in treatment effects was explored by considering 
potential treatment effect modifiers using meta-regression. Where appropriate, inconsistency 
between direct and indirect evidence was assessed using node-splitting. 
 
Results: 
46 randomised controlled trials (RCTs) were identified. Twenty seven RCTs provided 
fracture data and 35 RCTs provided BMD data for analysis.  Zoledronic acid was associated 
with the greatest treatment effect on vertebral fractures (HR 0.41, 95% CrI: 0.28,0.56) and 
percentage change in BMD (3.21, 95%: CrI 2.52,3.86) compared to placebo. The greatest 
treatment effect on non-vertebral and wrist fractures was given by risedronate (HR 0.72, 
95%: CrI 0.53,0.89 and HR 0.77, 95%: CrI 0.44,1.24, respectively). For hip fractures the 
greatest treatment effect was given by alendronate (HR 0.78, 95% CrI: 0.44,1.30). 
 
Conclusions: 
All treatments examined were associated with beneficial effects on fractures and femoral 
neck BMD relative to placebo.  For vertebral fractures and percentage change in femoral 
neck BMD the treatment effects were statistically significant for all treatments. Pairwise 
comparisons between treatments indicated that no active treatment was statistically 
significantly more effective than any other active treatment for fracture outcomes.   There 
was some heterogeneity in treatment effects between studies suggesting differential treatment 
effects according to study characteristics; however, there was no evidence of differential 
treatment effects with respect to gender and age. 
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1. Introduction 
 
Osteoporosis is a disease characterised by low bone mass and structural deterioration of bone 
tissue, with a consequent increase in susceptibility to fragility fracture (a broken bone 
resulting from a fall at standing height or less). Fractures cause significant pain, disability and 
loss of independence and can be fatal [1]. Osteoporosis affects over three million people in 
the UK [2].  Worldwide, osteoporosis causes more than 8.9 million fractures annually [3]. 
Bisphosphonates are a class of drug prescribed for the prevention of fragility fractures. In the 
UK, the National Institute for Health and Care Excellence (NICE) recommends alendronate 
for postmenopausal women at risk of fragility fracture for both primary prevention [4] and 
secondary prevention [5]. Risedronate is recommended for women who cannot take 
alendronate [4-6].  These recommendations currently do not include men and do not evaluate 
ibandronate or zoledronic acid.  Clinical effectiveness is considered by assessing fracture 
incidence as the primary efficacy outcome (vertebral, non-vertebral, hip and wrist) in 
randomised controlled trials (RCTs). 
Comparative effectiveness was evaluated using a network meta-analysis (NMA) to allow a 
comprehensive analysis of all evidence on all relevant treatments. NMAs can be used to 
combine direct and indirect evidence about treatment effects across RCTs that share at least 
one treatment in common with at least one other study [7]. Evidence reviews exist that 
evaluate alendronate, ibandronate, risedronate and zoledronic acid along with other 
treatments for osteoporosis and that have pooled fracture data across studies in a NMA [8-
11].   However, analyses are often limited by sparse data for specific skeletal sites and 
treatments. For example Ellis et. al [8] Jansen et.al [10] and Murad et. al. [11] do not include 
wrist fractures, and in [9] comparisons for this site are not available for ibandronate or 
zoledronic acid. Although the reporting of specific skeletal sites is disparate across the RCT 
evidence base, the majority also report change in femoral neck bone mineral density (BMD).  
Femoral neck BMD may be considered as a surrogate for fracture outcomes but, despite this, 
we are not aware of a published NMA for the effect of bisphosphonates on change in BMD.   
The purpose of the present study was to undertake a systematic review of the evidence base 
for alendronate, ibandronate, risedronate and zoledronic acid in the treatment of osteoporosis 
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and to present a NMA of both fracture outcomes and change in femoral neck BMD, from 
RCTs in men and women. 
Materials and Methods 
 
2.1. Review methods 
 
The review was undertaken in accordance with the general principles recommended in the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 
(http://www.prisma-statement.org/).  Searches were undertaken in MEDLINE and other 
databases to end of September 2014.  Contact with experts and reference checking was also 
undertaken to identify studies.  The results of the searches were sifted to identify potentially 
relevant studies that satisfy the inclusion/exclusion criteria by two independent reviewers 
(MMSJ and EG).  RCTs in men and women that evaluated alendronate, ibandronate, 
risedronate or zoledronic acid compared with each other or compared with placebo or other 
non-active treatments, and that reported fracture outcomes and/or BMD were eligible for 
inclusion. The primary outcomes for the NMA were, hip vertebral, non-vertebral, wrist, 
proximal humerus fractures and fragility fracture at other sites, and bone mineral density at 
the femoral neck assessed by dual energy X-ray absorptiometry (DXA). Details of outcome 
definition for each study are provided in Supplementary Table 2. Data were extracted from 
included studies by two independent reviewers (MMSJ and EG).  Data were extracted using a 
piloted data extraction form. Methodological quality of RCTs identified for inclusion was 
assessed using the Cochrane Collaboration risk of bias assessment criteria [12].   
1.1. Methods for the network meta-analysis 
A NMA was conducted for each of the four main fracture types, and for femoral neck BMD. 
An exchangeable treatment effects model was used (i.e. class effects model) where the 
treatment effects are assumed to arise from a common distribution according to the class of 
drug. For fracture outcomes, treatment effects are presented as hazard ratios (HR) relative to 
placebo, with a HR less than one reflecting a reduced risk of fracture relative to the 
comparator treatment. For femoral neck BMD, treatment effects are presented as the 
difference in mean percentage change from baseline in BMD relative to placebo after 1.8 
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years follow-up (the average duration of follow-up in these studies). Full details of the 
statistical model are given in the supplementary information.   
Where appropriate, heterogeneity in treatment effects was explored by considering potential 
treatment effect modifiers using meta-regression [13]. Baseline risk/response can be used as a 
proxy for differences in patient characteristics across trials that may be modifiers of treatment 
effect. Adjustment for baseline risk/response was assessed using the method of Achana et. 
al.[14]. 
Potential inconsistency between direct and indirect evidence was assessed using the node-
splitting method of Dias et al. [15]. In the case of fracture data, inconsistency was assessed 
for vertebral fractures only. For non-vertebral fractures, no indirect evidence was available. 
For hip and wrist fractures, an assessment of inconsistency was not performed because the 
direct evidence about treatment effect in the active comparator study is provided by one small 
study [16] with no events in each baseline arm, thereby providing imprecise evidence of 
treatment effect. 
All analyses were conducted in the freely available software package WinBUGS [17] and R 
[18], using the R2Winbugs [19] interface package.  Convergence to the target posterior 
distributions was assessed using the Gelman-Rubin statistic, as modified by Brooks and 
Gelman [20], for two chains with different initial values. For all outcomes, a burn-in of 
50,000 iterations of the Markov chain was used with a further 20,000 iterations retained to 
estimate parameters. Samples from the posterior distributions exhibited moderate correlation 
between successive iterations of the Markov chain so were thinned by retaining every 10th 
sample.  
The absolute goodness of fit was checked by comparing the total residual deviance to the 
total number of data points included in an analysis. The deviance information criterion (DIC) 
provides a relative measure of goodness-of-fit that penalises complexity and was used to 
compare different models for the same likelihood and data [21]. Lower values of DIC are 
favourable, suggesting a more parsimonious model. 
Results are presented using the posterior median treatment effects, 95% credible intervals 
(CrI) and 95% prediction intervals (PrI). The probability of each intervention ranking was 
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computed by counting the proportion of iterations of the Markov chain in which each 
intervention had each rank [22]. The treatment effects of each intervention compared to 
placebo together with the median rank and 95% CrI are displayed in forest plots for each 
outcome. 
2. Results 
2.1. Search results 
The searches identified 4,117 potentially relevant citations from searches of electronic 
databases after removal of duplicates.  A further 83 citations were identified from an existing 
evidence review commissioned by NICE [23].  Of these records, 4,054 were excluded at the 
title or abstract stage.  Full texts of 146 citations were obtained for scrutiny.  Of these, 87 
citations were excluded (the Table of excluded studies with reason for exclusion is presented 
as Supplementary Table 1).  A total of 46 RCTs [16, 24-68] reported across 59 citations were 
included in the review. The study selection process is fully detailed in the PRISMA flow 
diagram in Figure 1.  
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Figure 1: Flow diagram of study selection process (adapted from PRISMA)  
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Details of the included RCTs are provided in Supplementary Table 2.  Alendronate was 
evaluated against placebo in seventeen RCTs.  Daily oral ibandronate was evaluated against 
placebo in three RCTs and against i.v. administration in one RCT.  Daily administration of 
oral ibandronate was evaluated against monthly administration in one RCT.  Risedronate was 
evaluated against placebo in twelve RCTs, and zoledronic acid was evaluated against placebo 
in four RCTs.  One RCT evaluated alendronate compared with ibandronate, five RCTs 
evaluated alendronate compared with risedronate, one RCT evaluated zoledronic acid 
compared with alendronate, and one RCT evaluated zoledronic acid compared with 
risedronate.  The maximum trial duration was 48 months.  Details of inclusion and exclusion 
criteria for participants, number of patients randomised, outcomes reported and fracture and 
BMD assessments across the included studies are presented in Supplementary Table 2.  
 
 
)URP WKH &RFKUDQH ULVN RI ELDV DVVHVVPHQW DWWULWLRQ  DFURVV WUHDWPHQW JURXSV ZDV
evident for 29 (63%) of the included RCTs.  Five trials were reported as either open label or 
single blind and were considered at high risk of performance bias.  Blinded outcome 
assessment was only reported by 13 (29%) trials.  A summary of all risk of bias assessed by 
RCT is reported in Supplementary Figure 1.  A summary of each risk of bias item is 
presented in Supplementary Figure 2.   
 
2.2. Results of the network meta-analysis 
 
A total of 27 RCTs provided suitable fracture data for inclusion in the NMA and 35 RCTs 
provided suitable data for inclusion in the femoral neck BMD NMA. Network diagrams for 
each of the outcomes are presented in the supplementary material, along with an assessment 
of model fit. 
 
3.2.1. Vertebral fractures 
Vertebral fracture data were available from 21 RCTs, each comparing two treatments. The 
effects of each treatment relative to placebo are presented in Figure 2 and pairwise 
comparisons between treatments are provided in Supplementary Table 3. All treatments were 
associated with beneficial treatment effects relative to placebo. Zoledronic acid was 
associated with the greatest effect, HR 0.41 (95% CrI: 0.28, 0.56). Zoledronic acid was likely 
to be the most effective treatment (probability 0.44 of being the most effective; median rank 2 
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(95% CrI: 1, 5)), although there was insufficient evidence to differentiate between the 
interventions. The hazard ratio for a randomly chosen study for a new bisphosphonate is 0.45 
(95% PrI: 0.18, 1.11), with the reported prediction interval allowing for both between-study 
and between-treatment heterogeneity. 
Figure 2: Hazard ratios and 95% credible intervals (CrI) for the effect of treatment 
relative to placebo by fracture outcomes.  
 
Blue - pooled effects; Red - class effects; Grey: 95% prediction intervals (PrI). Median ranks and 95% CrI are 
displayed in the right hand column. 
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Within the network there were three treatment pairs for which both direct and indirect 
comparison were available (since the risedronate versus alendronate comparison is 
contributed by one small study with a zero count in the control arm, loops including this 
comparison were not included in the assessment of inconsistency). None of the comparisons 
showed significant evidence of inconsistency (Supplementary Table 11). 
 
3.2.2. Non-vertebral fractures 
Non-vertebral fracture data were available from 14 RCTs. All treatments were associated 
with beneficial treatment effects relative to placebo. Risedronate was associated with the 
greatest effect, HR 0.72 (95% CrI: 0.54, 0.89). Risedronate was likely to be the most 
effective treatment (probability 0.47 of being the most effective; median rank 2 (95% CrI: 1, 
5)), although there was insufficient evidence to differentiate between the interventions. The 
hazard ratio for a randomly chosen study for a new bisphosphonate is 0.79 (95% PrI: 0.39, 
1.64), allowing for both between-study and between-treatment heterogeneity. 
 
 
3.2.3. Hip fractures 
Hip fracture data were available from 10 RCTs. All treatments were associated with 
beneficial treatment effects relative to placebo, although the true treatment effects were 
inconclusive relative to placebo. Alendronate was associated with the greatest effect, HR 0.78 
(95% CrI: 0.45, 1.28). Alendronate was likely to be the most effective treatment (probability 
0.36 of being the most effective; median rank 2 (95% CrI: 1, 5)), although there was 
insufficient evidence to differentiate between the interventions. The hazard ratio for a 
randomly chosen study for a new bisphosphonate is 0.85 (95% PrI: 0.26, 2.81). 
 
3.2.4. Wrist fractures 
Wrist fracture data were available from 7 RCTs. All treatments were associated with 
beneficial treatment effects relative to placebo, although the true treatment effects were 
inconclusive relative to placebo. Risedronate was associated with the greatest effect, HR 0.76 
(95% CrI: 0.44, 1.25). Risedronate was likely to be the most effective treatment (probability 
0.43 of being the most effective; median rank 2 (95% CrI: 1, 4)), although there was 
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insufficient evidence to differentiate between treatments. The hazard ratio for a randomly 
chosen study for a new bisphosphonate was 0.85 (95% CrI: 0.26, 2.81). 
Heterogeneity in treatment effects between studies, and between bisphosphonates, is 
summarised in Table 1. The estimates of between-study standard deviation suggest mild 
(vertebral, non-vertebral), mild-moderate (wrist, hip) and moderate (hip) heterogeneity in 
treatment effects between RCTs, respectively. The estimates of between-treatment standard 
deviation indicate mild heterogeneity in effects between treatments (i.e., the effects of the 
bisphosphonates are relatively similar) but with considerable uncertainty. 
Baseline fracture risk can be used as a proxy for differences in patient characteristics across 
trials, that may be modifiers of treatment effect, and so introduce a potential source of 
heterogeneity in the NMA. The effect of baseline fracture risk as a potential treatment effect 
modifier was explored using meta-regression for all fracture types [14]. Based on a 
comparison of models with and without an adjustment for baseline risk, and inspection of the 
regression coefficients, there was no evidence that treatment effect varied with baseline risk 
for any of the fracture outcomes (see Table 2). 
 
Table 1: Heterogeneity between studies and bisphosphonate treatments, fracture outcomes. 
          
 
between-study  Between-treatment 
fracture type standard deviation 95% CrI standard deviation 95% CrI 
vertebral  0.19 (0.01,0.49) 0.18 (0.01,0.89) 
non-vertebral  0.09 (0.01,0.31) 0.17 (0.01,0.81) 
hip  0.43 (0.23,0.74) 0.19 (0.01,0.62) 
wrist  0.28 (0.03,0.65) 0.18 (0.01,0.63) 
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Table 2: Meta-regression on baseline fracture risk. Model summary for all fracture outcomes. 
          
 
Fracture type 
  vertebral non-vertebral hip wrist 
Baseline risk 0.03(-0.20,0.23) -0.08(-0.46,0.22) 0.43(-0.79,1.67) -0.40(-2.82,1.38) 
Between-study sd 0.20(0.01,0.52) 0.12(0.01,0.38) 0.4(0.06,0.75) 0.35(0.04,0.75) 
Between-treatment sd 0.13(0.01,0.46) 0.13(0.01,0.45) 0.19(0.01,0.63) 0.17(0.01,0.61) 
Total residual deviance 40.18 24.28 18.19 13.38 
data points 40 28 18 12 
DIC 69.78 44.84 32.86 23.75 
     Compare to model without covariates: DIC of 69.13 (vertebral), 43.04 (non-vertebral), 33.99 (hip), 23.06 
(wrist). 
 
 
3.2.5. Femoral neck BMD 
 
The sample mean ages of the participants in each study ranged from 50.5 to 78.5 years, with 
overall mean 64.1 years. Of the 35 RCTs included in the network, six RCTs included only 
male participants, 26 female, and three mixed. 
 
The effects of each treatment relative to placebo are presented in Figure 3 and pairwise 
comparisons between treatments are provided in Supplementary Table 12. All treatments 
were associated with beneficial treatment effects relative to placebo. Zoledronic acid was 
associated with the greatest effect, mean difference in percentage change in femoral neck 
BMD 3.20 (95% CrI: 2.51, 3.85). Zoledronic acid was likely to be the most effective 
treatment (probability 0.44 of being the most effective; median rank 2 (95% CrI: 1, 5)), 
although there was insufficient evidence to differentiate between treatments. The difference 
in mean change relative to placebo for a randomly chosen study for a new bisphosphonate is 
2.78 (95% PrI: 0.72, 4.77), with the reported prediction interval allowing for both between-
study and between-treatment heterogeneity. 
The between-study standard deviation was estimated to be 0.53 (95% CrI: 0.30, 0.86), 
implying moderate heterogeneity in treatment effects between RCTs. The between-treatment 
standard deviation was estimated to be 0.56 (95% CrI: 0.19, 1.70), which is indicative of 
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moderate heterogeneity in treatment effects between bisphosphonates (i.e., the effects of the 
bisphosphonates are more dissimilar) but with considerable uncertainty.  
To account for differing trial lengths, study duration was included as a trial level covariate. 
The estimated impact of duration of study on treatment effect, assuming a common 
relationship for each treatment, was 0.89 (95% CrI: 0.48, 1.18), indicating an increase in 
treatment effect with increasing duration of study, as expected.  
Based on comparison of models with and without a covariate for mean age, there was no 
evidence that treatment effect varied with age (Table 3). A meta-regression was conducted to 
test for different treatment effects according to the proportion of male participants. In line 
with the licensing indications, a covariate was not included for ibandronate treatments which 
are not licenced in men. There was no evidence that treatment effect varied by gender (Table 
3). 
 
The relationship between baseline response (the response in the placebo arm) and treatment 
effect was also assessed. There was evidence of an interaction between baseline response and 
treatment effect, with the interaction term estimated to be -0.46 (95% CrI: -0.76, -0.13) 
suggesting a larger treatment effect for studies that observed a more rapid decline in BMD 
under placebo treatment. However, including baseline response did not improve the fit of the 
model to the data according to a comparison of DICs (Table 6), therefore the evidence is 
inconclusive. 
 
Within the network there were nine treatment pairs for which both direct and indirect 
comparison were available. None of the comparisons showed significant evidence of 
inconsistency as assessed using Bayesian p-values (Supplementary Table 14). 
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Figure 3: Mean difference and 95% credible intervals (CrI) for the effect of treatment 
relative to placebo for percentage change in femoral neck BMD.  
 
Treatment effects represent the percentage change in BMD for a study of average duration (1.8 years). Blue - 
pooled effects; Red - class effects; Grey: 95% prediction intervals (PrI). Median ranks and 95% CrI are 
displayed in the right hand column. 
Table 3: Meta-regression, BMD. Model summary for all meta-regression models. 
        
 
meta-regression model 
  age gender baseline response 
covariate 0.01(-0.04,0.06) -0.79(-1.72,0.20) -0.46(-0.76,-0.13) 
between-study sd 0.55(0.31,0.89) 0.47(0.24,0.80) 0.51(0.31,0.78) 
between-treatment sd 0.56(0.18,1.73) 0.53(0.18,1.60) 0.5(0.19,1.38) 
total residual deviance 53.88 55.26 55.25 
data points 59 59 59 
DIC* 97.98 97.99 99.33 
    * compare to DIC of 96.95 for model without covariates 
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3. Discussion 
 
Network meta-analyses were used to synthesise the evidence and permit a coherent 
comparison of the efficacy of interventions in terms of fracture and femoral neck BMD for 
alendronate, ibandronate, risedronate and zoledronic acid.  As more RCTs presented data on 
femoral neck BMD than any of the individual fracture outcome types, the presented BMD 
network provides a richer evidence base for assessing potential treatment effect modifiers.   
The systematic review was based on rigorous methods, with comprehensive searches for 
evidence, a good level of consistency between reviewers in study selection and double 
checking of data extraction.  A formal assessment of methodological quality of included trial 
was undertaken.  From the assessment of methodological quality, aQ DWWULWLRQ ELDV 
across treatment groups was evident for 29 (63%) of the included RCTs.  Five trials were 
reported as either open label or single blind and were considered at high risk of performance 
bias.  Blinded outcome assessment was only reported by 13 (29%) trials.  The methodological 
quality of the evidence base should therefore be taken into consideration when interpreting 
these results.  Although the search strategy for this assessment report was comprehensive, the 
possibility of a publication bias cannot be discounted.  A formal assessment of publication 
bias was not undertaken.   
Adverse event data were widely reported across RCTs but are not reported here.  Patient 
compliance and persistence with treatment was not well reported across RCTs.  The majority 
of included trials typically excluded patients with underlying conditions or receiving 
medications that affect bone metabolism.  Furthermore, patients with a history of or receiving 
medication for upper gastrointestinal tract disorders were also excluded by the majority of 
included trials.  Therefore, the effects of alendronate, ibandronate, risedronate and zoledronic 
acid are unknown in these populations. 
We included RCTs evaluating current UK licensed doses of bisphosphonate for men and 
women.  Our searches identified only a limited number of RCTs in men.  Further research to 
assess efficacy and tolerability of bisphosphonate treatment in men may be beneficial. 
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In conclusion, all treatments were associated with beneficial effects on fractures and femoral 
neck BMD relative to placebo. The ranking of treatments varied across the different outcome 
types but there was insufficient evidence to differentiate between the interventions. There 
was some heterogeneity in treatment effects between studies suggesting differential treatment 
effects according to study characteristics; however, there was no evidence of differential 
treatment effects with respect to gender and age. 
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